

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 7 : C12Q 1/68		A2	(11) International Publication Number: WO 00/53804 (43) International Publication Date: 14 September 2000 (14.09.00)
(21) International Application Number: PCT/GB00/00761 (22) International Filing Date: 3 March 2000 (03.03.00) (30) Priority Data: 9904991.8 5 March 1999 (05.03.99) GB		(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>Without international search report and to be republished upon receipt of that report.</i>	
(71) Applicant (for all designated States except US): THE UNIVERSITY OF NOTTINGHAM [GB/GB]; University Park, Nottingham NG7 2RD (GB). (72) Inventor; and (75) Inventor/Applicant (for US only): ARMOUR, John, Anthony [GB/GB]; The University of Nottingham, University Park, Nottingham NG7 2RD (GB). (74) Agent: WOMSLEY, Nicholas; Swindell & Pearson, 48 Friar Gate, Derby DE1 1GY (GB).			
(54) Title: GENETIC SCREENING (57) Abstract <p>A method of screening for nucleic acid sequence copy number in a sample genetic material (10), the method including introducing a number of different genetic probes (14) to hybridise with the genetic sample (10). The probes (14) are flanked by the same or substantially the same primer binding sites thereby enabling amplification of sample-bound probes using a single primer pair and thus the screening of different sequence copy numbers at the same time.</p>			

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

Genetic Screening

The present invention relates to screening for sequence copy number and in particular to screening for changes in copy number of a plurality of nucleic acid sequences substantially simultaneously.

The loss or reduction in the normal number of copies of a genetic sequence (deletion) or the increase in copy number (amplification) are of widespread general importance. Such genetic alterations are known to underlie phenotype characteristics both somatic and germline including disorders as diverse as idiopathic mental retardation and neoplasia. The demonstration of the site and nature of such genetic alteration is critical in the identification of the genes responsible and to the development of appropriate and effective treatments and therapies.

In principle, it is possible to screen for genetic deletions by using Southern blot hybridisation. However, this method requires heterozygosity, and whilst the loss of heterozygosity at polymorphic loci can be used to demonstrate the absence of one allele in the soma or in the germline, its effectiveness is limited by the requirement for heterozygosity and the number of repeated tests needed to screen even a small fraction of the genome.

If sufficient precautions are taken to assure quantitative yields, the polymerase chain reaction (PCR) can be used to screen for copy number, and specialised systems have been developed to assure quantitative PCR by following the accumulation of products as amplification proceeds. However, such systems do not provide for the satisfactory analysis of a plurality of alterations substantially simultaneously.

According to the present invention there is provided a method of screening for copy number of target nucleic acid sequences in a sample of genetic material, the method comprising introducing to the sample a plurality of different genetic probes suitable to hybridise with respective target

sequences and all flanked by the same or substantially the same primer binding sites, subjecting the sample to conditions favouring hybridisation of the probes to their respective sequences, and amplification of sample-bound probes using a pair of primers, wherein analysis of the respective amounts of amplified probe provides for quantitative determination of the copy number of the respective nucleic acid sequences in the sample.

Preferably each probe is distinguishable from the other(s), for example by having distinguishing mobility characteristics through a separating gel. Preferably the plurality of different probes comprises a predetermined set of different probes each chosen to be specific for a respective target nucleic acid sequence. The set may comprise probes suitable to screen a plurality of different nucleic acid sequences simultaneously or substantially simultaneously such that determination of the quantity of each probe product produced, preferably using the polymerase chain reaction (PCR), enables quantitative determination of the copy number of the respective sequences in the sample. The method may be used to screen sequences of different genes or different sequences within a gene, such as different exons in a eukaryotic gene. Preferably the method is used to detect genetic alterations such as genetic deletions (reduction in sequence copy number) and genetic amplification (increase in sequence copy number).

Preferably the genetic material is immobilised prior to hybridisation, such that hybridised flanking primers are likewise immobilised. Preferably an excess of probes is used.

Probes labelled for ready identification, such as with fluorescent labels are preferably used. More than one set of probes may be used, either simultaneously or sequentially. The flanking primer pairs may be the same or different for each set of probes.

Preferably the method comprises means to obviate or mitigate hybridisation between primer binding sequences. Competing oligonucleotides

may be introduced to the sample preferably during the hybridisation stage to releasably bind to the primer binding sites flanking each probe whereby to mitigate primer binding site interactions.

Preferably unbound probes and primers are thoroughly washed away from the bound probes following hybridisation stage and prior to analysis.

The method may be used to screen DNA, RNA and/or cDNA with appropriate probe sets. The method may be used to screen somatic and/or germline sequences. The method may be used to screen for polymorphic alterations.

The invention further provides a set of probes substantially as described above in any of the preceding seven paragraphs.

The invention may still further comprise a kit for such a method described above in any of the preceding eight paragraphs, which kit comprises a probe set generally as defined above, amplification primers and means to enable amplification and analysis of amplification product(s).

The present invention will now be described by way of example only with reference to the accompanying drawings, in which:-

Fig. 1 is a simple schematic illustration of a method according to the invention;

Fig. 2 shows a gel run produced from samples from four unrelated humans using the method according to the present invention;

Fig. 3 shows an enlargement of the central region III of the gel in Fig. 2;

Fig. 4 shows the results of quantitative analysis of the region III of the gel from one male sample (upper trace) and one female (lower trace);

Fig. 5 shows the relative signal from different probes shown plotted against probe size;

Fig. 6 shows the *Eco*RV cloning site of pZero2 and the corresponding

primer combination (PZA and PZB) used to generate probes from fragments cloned into the *EcoRV* site.

With reference to Fig. 1, there is provided a method of screening for copy number of target nucleic acid sequences in a sample of genetic material, the method comprising introducing to the sample a plurality of different genetic probes suitable to hybridise with respective target sequences and all flanked by the same or substantially the same primer binding sites, subjecting the sample to conditions favouring hybridisation of the probes to the respective sequences, and amplification of sample-bound probes using a pair of flanking primers, wherein analysis of the respective amounts of amplified probe provides for quantitative determination of the copy number of the respective nucleic acids sequences in the sample.

The method can be used to screen for genetic alterations, in particular deletions and amplifications in copy number of genetic sequences, both somatic and germline.

The sample of genetic material to be screened, which may comprise, DNA, cDNA and/or RNA, shown diagrammatically in Fig. 1 (10), is reversibly immobilised on a medium (12) such as a nylon filter.

A plurality of probes (14) is designed and prepared to seek out and hybridise with specific nucleic acid sequences, if present in the sample. The probes (14) are chosen to comprise a set of different probes each type operable to seek out a different respective nucleic acid sequence which may be sequences suspected of being involved in a particular disorder or condition for example, in the organism from which the sample has been taken. Alterations in the copy number of particular genetic sequences are known to be involved in conditions such as cancer and mental retardation, and probes specific for these sequences can be prepared and comprised in a probe set used in accordance with the present methodology for example where certain symptoms suggest these disorders or diseases may be involved.

When an appropriate probe set is created or identified, it is then introduced to the immobilised genetic material in stoichiometric excess under conditions favouring hybridisation of the probes to their respective nucleic acid sequences, if present.

Once sufficient time has elapsed to provide for hybridisation, unbound probes are washed thoroughly away and the PCR employed to amplify bound probes.

The use of the same primer pair binding sites flanking all the different probes is important to the successful operation of this method, and allows different bound probes to be amplified together with a single primer pair and thus the screening for a plurality of different loci at the same time.

Some interaction has been experienced between primer binding sites flanking different probes, but this problem has been addressed by adding to the hybridisation solution an excess of competing oligonucleotides which releasably bind to the respective primer binding sites thereby preventing such undesirable interactions whilst not adversely affecting the subsequent amplification process. The oligonucleotides are displaced once hybridisation of the probes to the sample is complete, to provide for hybridisation of the amplification primers to the binding sites.

Respective sets of probes can be made either by ligation to oligonucleotide adapters, or more simply by preparing the probes as inserts into the same site of a cloning vector, and using primers flanking the cloning site for amplification. Fig. 6 shows the cloning site of the vector pZero2 (sequence provided by InVitrogen: <http://www.invitrogen.com/vecseq-gcg/pzero2.seq>), showing the primers PZA and PZB flanking the *Eco*RV site (lowercase) used to clone blunt-ended fragments. Products amplified using these primers are therefore 59bp longer than the cloned inserts. It is thus possible to prepare sets of probes, each detecting a different locus, but all flanked by the same primer-binding sites.

It is important that a probe set is created such that each contributing probe is distinguishable, for example by virtue of its mobility through a separating gel. Following amplification, the appearance of a product of corresponding mobility acts to report the presence of a particular nucleotide sequence, and hence the presence of that sequence in the target sample. As an excess of probe is used, and amplification is restricted to the quantitative phase, the absolute amount of each product reflects its copy-number in the sample tested. Different probes may amplify with different efficiencies, but the proportional contribution from each probe will reflect its dosage in the sample and can be inferred from comparisons between different samples examined with the same probe set. As it is the retained probe that is amplified, not the sample, the gel mobility of the product is not influenced by the presence (for example) of Restriction Fragment Length Polymorphism (RFLPs) at that locus.

The following outlines experiments conducted using the method of the present invention to screen a plurality of different genetic sequences simultaneously. A set of 43 amplifiable probes was generated by cloning blunt-ended fragments into the *EcoRV* site of *pZero2* (Fig. 6), followed by amplification with vector primers flanking this site, and selection of a mix of probes of different lengths. This mix included probes from 7 autosomes (1, 5, 11, 16, 17, 18 and 22), as well as the X and Y chromosomes.

The initial mix of 43 probes was subcloned from plasmids and plasmid fragments known from sequencing or hybridisation not to contain dispersed repeat elements; in the case of one of the Y-linked probes (SRY), a 1360bp fragment was amplified using primers SRYA (5'GCAGTAGAGCAGTCAGGGAG3') and SRYB (5'GGGGAGAGAAAGAAACAAGTTG3'). Other sources of cloned genomic DNA were: chromosome 1, pJBT2 (JALA, unpublished); chromosome 5, pMS621 (Armour et al., 1996); chromosome 11, pEJ6.6 (Goldfarb et al., 1982); chromosome 16, pRN6N6A (JALA and R.M. Badge, unpublished); chromosome 17, pYNZ22 (Nakamura et al., 1988); chromosome 18, pMS440 (Armour et al., 1990); chromosome 22, pMS632c (Armour et al., 1995); chromosome X, pMS613 (Armour et al., 1990). After isolation of the genomic insert and digestion with

frequently-cutting restriction enzymes producing blunt ends (generally double digestion with *Alu*I plus *Hae*III), the resulting smaller fragments were cloned into the *Eco*RV site of pZero2 (InVitrogen) and propagated in *E.coli* TOP10 (InVitrogen). Care was taken to avoid repeat regions in DNA from minisatellite-containing clones.

With reference to Fig. 6, probes prepared by cloning blunt-ended restriction fragments from primary clones into the *Eco*RV site of pZero2 (InVitrogen) were amplified directly from bacterial cells (Sandhu et al., 1989) using flanking vector primers PZA (5'AGTAACGGCCGCCAGTGTGCTG3') and PZB (5'CGAGCGGCCGCCAGTGTGATG3'). The positions of these primers in the pZero-2 cloning site is shown in figure 6. PCR was carried out in Advanced Biotechnologies Buffer IV (75mM Tris-HCl pH8.8, 20mM (NH₄)₂SO₄, 0.01% Tween), with 0.2mM each dNTP, 1mM MgCl₂, 0.2μM each primer and 0.05U/μl Taq DNA polymerase (Advanced Biotechnologies). Reactions (generally 10μl) were subjected to 25 cycles of (95°C for 1 minute/70°C for 1 minute). Products amplified using ³³P end-labelled PZA were separated on denaturing 6% polyacrylamide/50% urea gels and probe mixes assembled such that the mobilities of all constituent probes were distinct.

Sample DNA for immobilisation was prepared in an initial volume of less than 5μl, denatured by addition of 1μl 1M NaOH, and spotted onto a nylon filter (MSI MAGNA, approximate dimensions 2mm x 4mm), 1μl at a time, allowing the solution to dry between applications. When all the DNA had been added the DNA was irreversibly bound to the filter using U.V. irradiation. Since numerous filters were to be used in the same hybridisation, individual marks cut into the edges and corners made clear the identity of each filter.

Filters were prehybridised in 1ml of prehybridisation solution (0.5M sodium phosphate pH7.2, 7% SDS, 0.1mg/ml alkali-denatured herring sperm DNA) at 65°C overnight, and before hybridisation this was exchanged for 200μl of prehybridisation solution with the addition of denatured human Cot-1 DNA (Gibco BRL) to a final concentration of 10μg/ml. Probe mixtures containing

about 100pg of each sequence in 1 μ l were mixed with 7 μ g *E.coli* DNA (DH5 α DNA, digested with *Hae*III) and 1 μ g human Cot-1 DNA (Gibco-BRL), and denatured by adding 2 μ l 1M NaOH. After 1 minute at 37°C, the probe mixture was placed on ice, neutralized by adding 3 μ l 1M NaH₂PO₄, and added to the hybridisation solution.

Hybridisation was left to proceed at 65°C overnight, and the filters were thoroughly washed at 65°C in (a) two 1ml changes of prehybridisation solution, (b) 200ml 1x SSC/1% SDS and (c) 500ml 0.1x SSC 0.1% SDS. Washed filters were then transferred to individual 50 μ l amplification reactions (constituents as for probe amplification), and bound DNA amplified for 5 cycles of 95°C 1 minute/70°C 1 minute.

This low-level preamplified solution was then used to seed further 10 μ l amplifications using ³³P 5' end-labelled primer PZA. Labelled PCR products were given a final incubation at 72°C for 20 minutes (to drive to completion the addition of untemplated A at the 3' ends), an equal volume of formamide dye mix (98% formamide, 10mM EDTA pH 8.0, 1mg/ml xylene cyanol FF, 1mg/ml bromophenol blue) added, and the DNA denatured at 100°C for 2 minutes and then placed on ice. From this denatured sample, 4 μ l was loaded into a well of a 6% polyacrylamide/50% urea gel in 0.5x TBE, and the gel run at 90W (to maintain a gel temperature of about 45°C) until the xylene cyanol dye was close to the end of the gel. Gels were fixed in 10% methanol/10% acetic acid, dried, and radioactivity detected either by standard autoradiography or (for quantitative analysis) using ImageQuant software analysis on data captured by a storage phosphorimager screen (Molecular Dynamics).

The screening results of hybridising this probe set with DNA from one male and three females is shown in figure 2. The autosomal loci give comparable signals, between all individuals; while there is probe-to-probe variation in absolute intensity, the relative contribution of each band to the whole is highly reproducible. By contrast, the Y-derived probes only give strong signals in the hybridisation with male DNA. The relative signal from the X-

linked probes is reduced by about 50% in the male (figures 3 and 4).

In figure 5, the normalised relative signal from each probe is shown plotted against the length of the probe; signal intensities are normalised relative to the mean value for that probe among all individuals tested for autosomal loci, among all the females for X-linked probes and relative to the male for Y-linked probes. The boxed points are the points for X-linked loci in the male (about 50% signal intensity) and for Y-linked probes in females (close to zero). This experiment models the expected detection of homozygous deletions (Y-linked loci in females) or hemizygous deletions (X-linked loci in males). In the size range 140-600bp the signal appears to reflect copy number variation consistently.

Nearly all the amplified bands seen after hybridisation corresponded in size with the expected probes. There were however three bands (marked with asterisks on figure 2) which did not correspond to probes of known origin; the largest of these is clearly Y-linked. The simplest explanation for the appearance of these bands is that they are the result of contamination of the probe mix by other probes made at the same time. Since (if hybridisation has gone to near completion) the intensity of the band recovered from a target DNA will depend on its copy-number in the target DNA, and not on its concentration in the probe mix, even relatively minor contamination with additional probes could result in the appearance of unexpected bands in the amplified product at intensities equal to the predicted bands. Probe fragments corresponding to two of these additional bands are detectable as components of the initial probe mix. The importance of avoiding even minor contamination with additional probes represents an advantage of isolating and storing the probes as clones (rather than PCR products), since uncontaminated probe preparations can be reconstituted from colony-purified clones.

The efficiency of this method derives from its ability to examine numerous loci simultaneously (in this experiment, 43 probes). In the format used here, in which radiolabelled probes are resolved using denaturing

polyacrylamide gel electrophoresis, the number of probes which can be analysed simultaneously is limited only by the resolving power of the gel. Since probes in the size range 140-600bp have been used successfully in this experiment, careful size-selection of probes could lead to probe sets containing more than a hundred probes, which might (for example) be used as chromosome-specific subsets to analyse copy number at megabase resolution.

Moreover, greater resolution may be achieved using fluorescently-labelled probes and apparatus and software designed for automated sequence analysis. This would not only have the advantage of single-base resolution over a larger range (and hence the possibility of more probes per lane), but could also use multiple fluors in a single track. Thus if (for example) four sets of each of 100 probes were assembled, the probes of each set flanked by different primer binding sites (same within a set), they could be hybridised with the same target, and after the initial recovery of bound probes and low-level preamplification using all primer pairs, each set could be selectively amplified with its own primer pair (one fluorescent), and the four resulting sets of fluorescent products mixed and run in the same lane. Similarly, if the same primer was available with different fluorescent labels, then a direct comparison between two samples (for example tumour versus normal from the same person) could be made by labelling the products from each with different fluors and running in the same lane of the gel.

In the present format, the high resolution of polyacrylamide gel electrophoresis allows the simultaneous differentiation of products from many different loci, but even using all the available "slots" with judicious assembly of probe sets, this format probably limits the number of probes flanked by a given primer pair which can be resolved in one lane to about 500, and hence if four probe sets with different flanking primers can be used simultaneously, fewer than 2000 probes can be examined simultaneously in this test. It might be possible to augment the resolution of this analysis by using formats for the quantitative detection of amplified probe which do not rely on gel electrophoresis. One alternative would be to use recovered probes to label

arrays of the clones from which the probes themselves were produced; a procedure analogous to array-CGH (Pinkel et al., 1998), but with the added efficiency that the method according to the present invention the MAPH has already produced proportionate amounts of the relevant single-copy probes from the genomic targets, reducing the complexity of the mixture (for increased speed of hybridisation) and by avoiding multi-copy sequences, presumably allowing quantification with a greater signal:noise ratio.

The experiments explained here have used genomic DNA as the target nucleic acid, but an extension of this method would be to use probes to probe RNA (or cDNA) for highly parallel analysis of gene expression. Current RT-PCR based methods for quantification of gene expression do not allow the simple analysis of numerous loci simultaneously.

The method could be used to screen for alterations to a plurality of sequences relating to different genes, and/or sequences within a target gene e.g. screen for alterations in exon copy number within a eukaryotic gene.

Using the method according to the present invention to detect deletions and amplifications in (for example) idiopathic mental retardation (IMR) assumes that the absence of a locus is abnormal, rather than resulting from a polymorphism. This can be most simply investigated by analysis of the parents in cases of IMR, but it remains possible that wider application of this technique will uncover loci at which there are presence/absence polymorphisms. If enough (sufficiently informative) loci of this kind were available, then assembly of such probes into a mutually compatible "polymorphic set" would allow simultaneous genotyping at (say) 50-100 loci in a single lane of a sequencing gel; combined with analysis of mixed DNA samples, such a system could provide very high throughput for genotyping without the need for investment in expensive or complicated equipment.

Whilst endeavouring in the foregoing specification to draw attention to those features of the invention believed to be of particular importance it should

be understood that the Applicant claims protection in respect of any patentable feature or combination of features hereinbefore referred to and/or shown in the drawings whether or not particular emphasis has been placed thereon.

CLAIMS


1. A method of screening for copy number of target nucleic acid sequences in a sample of genetic material (10), the method comprising introducing to the sample (10) a plurality of different genetic probes (14) suitable to hybridise with respective target sequences and all flanked by the same or substantially the same primer binding sites, subjecting the sample (10) to conditions favouring hybridisation of the probes (14) to their respective sequences, and amplification of sample-bound probes (14) using a pair of primers, wherein analysis of the respective amounts of amplified probe (14) provides for quantitative determination of the copy number of the respective nucleic acid sequences in the sample (10).
2. A method according to claim 1, characterised in that each probe (14) is distinguishable from the other(s), for example by having distinguishing mobility characteristics through a separating gel.
3. A method according to claim 1 or 2, characterised in that the plurality of different probes (14) comprises a predetermined set of different probes (14) each chosen to be specific for a respective target nucleic acid sequence.
4. A method according to claim 3, characterised in that the set comprises probes (14) suitable to screen a plurality of different nucleic acid sequences simultaneously or substantially simultaneously such that determination of the quantity of each probe product produced enables quantitative determination of the copy number of the respective sequences in the sample.
5. A method according to claim 4, characterised in that the polymerase chain reaction is used to determine the quantity of each probe product produced.
6. A method according to any of the preceding claims, characterised in that the method is used to screen sequences of different genes or different

sequences within a gene, such as different exons in a eukaryotic gene.


7. A method according to any of the preceding claims, characterised in that the method is used to detect genetic alterations such as genetic deletions (reduction in sequence copy number) and genetic amplification (increase in sequence copy number).
8. A method according to any of the preceding claims, characterised in that the genetic material (10) is immobilised prior to hybridisation, such that hybridised flanking primers are likewise immobilised.
9. A method according to any of the preceding claims, characterised in that an excess of probes (14) is used.
10. A method according to any of the preceding claims, characterised in that probes (14) labelled for ready identification are used.
11. A method according to claim 10, characterised in that probes labelled with fluorescent labels are used.
12. A method according to any of claims 3 to 11, characterised in that more than one set of probes (14) is used, either simultaneously or sequentially.
13. A method according to claim 12, characterised in that the flanking primer pairs are the same for each set of probes (14).
14. A method according to claim 12, characterised in that the flanking primer pairs are different for each set of probes (14).
15. A method according to any of the preceding claims, characterised in that the method comprises means to obviate or mitigate hybridisation between primer binding sequences.

16. A method according to claim 15, characterised in that competing oligonucleotides are introduced to the sample preferably during the hybridisation stage to releasably bind to the primer binding sites flanking each probe whereby to mitigate primer binding site interactions.
17. A method according to any of the preceding claims, characterised in that unbound probes (14) and primers are thoroughly washed away from the bound probes (14) following hybridisation stage and prior to analysis.
18. A method according to any of claims 3 to 17, characterised in that the method is used to screen DNA, RNA and/or cDNA with appropriate probe sets.
19. A method according to claim 18, characterised in that the method is used to screen somatic and/or germline sequences.
20. A method according to claim 18 or 19, characterised in that the method is used to screen for polymorphic alterations.
21. A set of probes (14) substantially as described above in any of the preceding claims.
22. A kit for such a method described above in any of the preceding claims, which kit comprises a probe set (14) generally as defined above, amplification primers and means to enable amplification and analysis of amplification product(s).
23. A method of screening for copy number of target nucleic acid sequences in a sample of genetic material substantially as hereinbefore described with reference to the accompanying examples and drawings.
24. A set of probes substantially as hereinbefore described with reference to the accompanying examples and drawings.

25. A kit for a method of screening for copy number of target nucleic acid sequences in a sample of genetic material substantially as hereinbefore described with reference to the accompanying examples and drawings.
26. Any novel subject matter or combination including novel subject matter disclosed herein, whether or not within the scope of or relating to the same invention as any of the preceding claims.



FMFF


FIG. 2

F *M* *F* *F*

22 → 

Y → 

X → 

X → 
17 → 

22 → 


Y → 

X → 

17 → 

FIG. 3

4/6






Fig. 6

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
14 September 2000 (14.09.2000)

PCT

(10) International Publication Number
WO 00/53804 A3

(51) International Patent Classification⁷: **C12Q 1/68**

(21) International Application Number: **PCT/GB00/00761**

(22) International Filing Date: 3 March 2000 (03.03.2000)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
9904991.8 5 March 1999 (05.03.1999) GB

(71) Applicant (for all designated States except US): **THE UNIVERSITY OF NOTTINGHAM [GB/GB]; University Park, Nottingham NG7 2RD (GB).**

(72) Inventor; and

(75) Inventor/Applicant (for US only): **ARMOUR, John, Anthony [GB/GB]; The University of Nottingham, University Park, Nottingham NG7 2RD (GB).**

(74) Agent: **WOMSLEY, Nicholas; Swindell & Pearson, 48 Friar Gate, Derby DE1 1GY (GB).**


(81) Designated States (national): AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:
— With international search report.

(88) Date of publication of the international search report: 21 December 2000

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.



WO 00/53804 A3

(54) Title: **GENETIC SCREENING**

(57) Abstract: A method of screening for nucleic acid sequence copy number in a sample genetic material (10), the method including introducing a number of different genetic probes (14) to hybridise with the genetic sample (10). The probes (14) are flanked by the same or substantially the same primer binding sites thereby enabling amplification of sample-bound probes using a single primer pair and thus the screening of different sequence copy numbers at the same time.

INTERNATIONAL SEARCH REPORT

International Application No
PCT/GB 00/00761

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 C12Q1/68

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 7 C12Q

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

BIOSIS, EPO-Internal

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
T	ARMOUR ET AL: "MEASUREMENT OF LOCUS COPY NUMBER BY HYBRIDISATION WITH AMPLIFIABLE PROBES" NUCLEIC ACIDS RESEARCH, GB, OXFORD UNIVERSITY PRESS, SURREY, vol. 28, no. 2, 2000, pages 605-609, XP002138423 ISSN: 0305-1048 the whole document ---	1-22
A	WO 93 04199 A (SCIENT GENERICS LTD) 4 March 1993 (1993-03-04) claim 1 ---	1,21
A	WO 90 06042 A (HOLMES MICHAEL JOHN ;DYNAL AS (NO)) 14 June 1990 (1990-06-14) claim 1 ---	1,21
		-/-

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "&" document member of the same patent family

Date of the actual completion of the international search

29 September 2000

Date of mailing of the international search report

06/10/2000

Name and mailing address of the ISA
European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl.
Fax: (+31-70) 340-3016

Authorized officer

Osborne, H

INTERNATIONAL SEARCH REPORT

International Application No
PCT/GB 00/00761

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category ^a	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 99 07892 A (UNIV CALIFORNIA) 18 February 1999 (1999-02-18) page 2, line 19 -page 3, line 2 ---	1
E	WO 00 43538 A (UNIV MONTREAL ; BRUKNER IVAN (CA); PAQUIN BRUNO (CA); TREMBLAY GUY) 27 July 2000 (2000-07-27) figure 1 ---	21
A	WO 98 15649 A (CREMER THOMAS ; CRAIG JEFF (DE); UNIV HEIDELBERG (DE)) 16 April 1998 (1998-04-16) figure 1 ---	21
A	HILL J M ET AL: "QUANTITATIVE ANALYSIS OF POLYMERASE CHAIN REACTION PRODUCTS BY DOT BLOT" ANALYTICAL BIOCHEMISTRY, US, ACADEMIC PRESS, SAN DIEGO, CA, vol. 235, no. 1, 1 March 1996 (1996-03-01), pages 44-48, XP000552019 ISSN: 0003-2697 the whole document ----	1
A	REISCHL U ET AL: "QUANTITATIVE PCR A SURVEY OF THE PRESENT TECHNOLOGY" MOLECULAR BIOTECHNOLOGY, US, TOTOWA, NJ, vol. 3, 1995, pages 55-71, XP000600241 ISSN: 1073-6085 the whole document -----	1

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

Claims Nos.: 26 and partially 23-25.

Claims 23-26 do not meet the requirements of Article 6 PCT. The subject matter for which protection is sought in claims 23-26 is imprecisely defined. Claims 23-25 make reference in their formulations to subject matter in "the accompanying examples and drawings" without specifying which examples or drawings are precisely being referred to. Thus, for example, although a method and the probes for use used in the method may be determined from fig. 1, no similar information as to either can be extracted from figs 2-6. In consequence, the subjected matter searched in claims 23-25 were restricted to the following: Claim 23: to the method defined in claim 1 and pictorially represented in fig.1; Claims 24 and 25: to the probes and a Kit for performing the method of claim 1 and pictorially represented in Fig. 1. No subject matter is defined in the formulation of claim 26. Consequently, this claim was not searched.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/GB 00/00761

Patent document cited in search report		Publication date	Patent family member(s)		Publication date
WO 9304199	A	04-03-1993	NONE		
WO 9006042	A	14-06-1990	AT 102256 T		15-03-1994
			AT 93896 T		15-09-1993
			AU 640626 B		02-09-1993
			AU 4758690 A		26-06-1990
			AU 634993 B		11-03-1993
			AU 4759690 A		26-06-1990
			CA 2003501 A		21-05-1990
			CA 2003508 A		21-05-1990
			DE 68908900 D		07-10-1993
			DE 68908900 T		20-01-1994
			DE 68913555 D		07-04-1994
			DE 68913555 T		07-07-1994
			WO 9006045 A		14-06-1990
			EP 0446260 A		18-09-1991
			EP 0444120 A		04-09-1991
			JP 4501956 T		09-04-1992
			JP 3020271 B		15-03-2000
			JP 4501959 T		09-04-1992
			US 5512439 A		30-04-1996
WO 9907892	A	18-02-1999	US 6066453 A		23-05-2000
			EP 1012332 A		28-06-2000
WO 0043538	A	27-07-2000	NONE		
WO 9815649	A	16-04-1998	AU 4116397 A		05-05-1998
			EP 0951566 A		27-10-1999